A commonly prescribed class of blood-thinning medicines may do more than prevent strokes in people living with both atrial fibrillation and Alzheimer’s disease. A nationwide Swedish study suggests that patients taking newer oral anticoagulants, known as non-vitamin K antagonist oral anticoagulants, or NOACs, experienced a slower decline in cognitive performance than comparable patients treated with the older drug warfarin or with no anticoagulant treatment. The difference was modest on an individual-year basis, but researchers say it could become clinically meaningful when accumulated over several years, potentially influencing how long patients preserve memory, orientation and everyday reasoning abilities.
Atrial fibrillation is the most common sustained heart rhythm disorder, particularly in older adults. Instead of contracting in a regular rhythm, the heart’s upper chambers quiver irregularly, allowing blood to stagnate and form clots. If a clot travels to the brain, it can block an artery and cause an ischemic stroke. Even without a major, recognizable stroke, however, atrial fibrillation may be associated with repeated tiny disruptions in cerebral blood flow. These small vascular injuries, sometimes called silent infarcts or microinfarcts, can accumulate over time and contribute to cognitive impairment. Anticoagulants reduce the blood’s ability to form clots, lowering the risk that these events will damage the brain.
The new analysis used data from SveDem, Sweden’s national quality register for cognitive disorders and dementia. Researchers identified 7,308 people diagnosed with both Alzheimer’s disease and atrial fibrillation and compared their outcomes according to anticoagulant treatment. To make the groups more comparable, the investigators created matched cohorts consisting of patients taking NOACs, patients receiving warfarin, and patients who were not using an anticoagulant. Cognitive change was tracked with the Mini-Mental State Examination, or MMSE, a standardized screening tool that assesses orientation, memory, attention, language and the ability to perform simple calculations and commands.
Patients receiving NOACs showed a significantly slower decline in MMSE scores than those treated with warfarin or those receiving no anticoagulant medication. The reported difference was just over 0.2 MMSE points per year. That figure may sound small, especially because MMSE scores can fluctuate with fatigue, illness, education, hearing difficulties and other factors. Yet Alzheimer’s disease is progressive, and a small shift in the average annual rate can become more substantial over a longer period. The researchers therefore argue that the result deserves attention not because NOACs reverse Alzheimer’s disease, but because they may modestly alter the pace at which cognitive abilities deteriorate.
The biological explanation remains plausible but unproven. Warfarin and NOACs both reduce clot formation, but they act through different pathways. Warfarin interferes with the production of several vitamin K-dependent clotting proteins and requires regular blood tests to keep its effect within a narrow therapeutic range. NOACs, including drugs that directly inhibit thrombin or factor Xa, target specific components of the coagulation cascade and generally produce more predictable anticoagulation. More stable protection against clot formation could theoretically reduce repeated microscopic vascular injury. Improved prevention of embolic events might also preserve brain networks that are especially vulnerable in people already affected by Alzheimer’s pathology.
The study found benefits beyond cognitive measurements. Compared with people who received no anticoagulant treatment, those taking NOACs had lower risks of death, stroke, blood clots and fractures. Warfarin was also associated with lower risks of death, stroke and thromboembolic events. However, warfarin users faced a higher risk of major bleeding, an important concern because anticoagulants can cause serious hemorrhages, including bleeding inside the brain. NOACs are not risk-free, and their safety can be affected by kidney function, age, weight, interactions with other medicines and whether doses are taken consistently. Decisions about treatment must therefore balance protection from clotting against the possibility of dangerous bleeding.
The researchers emphasize that the findings do not prove that NOACs directly slow Alzheimer’s disease. This was an observational study, meaning that the investigators examined patterns in existing medical records rather than randomly assigning patients to different medications. People prescribed NOACs may have differed from other participants in ways that also influenced cognition. For example, they may have had better access to medical care, fewer additional illnesses, different levels of frailty, or clinical characteristics that made doctors more comfortable prescribing a newer anticoagulant. Although statistical matching can reduce some differences between groups, it cannot eliminate every source of confounding.
Medication changes create another complication. Some patients may have moved from warfarin to a NOAC, stopped treatment, restarted it, or changed drugs because of bleeding, worsening health or changes in kidney function. If treatment exposure is not constant, assigning a person to one group may not perfectly represent the medication experience over the entire follow-up period. Cognitive testing also has limitations. The MMSE is useful for tracking broad changes in cognition, but it is not a complete measure of executive function, processing speed, mood, behavior or the ability to manage complex daily activities. Future studies could strengthen the evidence by combining detailed neuropsychological testing with brain imaging, laboratory data and longer follow-up.
The findings nevertheless add to a growing scientific discussion about the relationship between cardiovascular health and neurodegeneration. Alzheimer’s disease is defined by abnormal accumulation of amyloid and tau proteins, but the condition does not develop in isolation from the circulatory system. Blood vessels supply oxygen and nutrients to brain cells, help remove waste products and regulate the blood-brain barrier. Atrial fibrillation, high blood pressure, diabetes and other vascular conditions can place additional stress on this system. Preventing strokes and smaller clot-related injuries may not remove the underlying molecular causes of Alzheimer’s disease, but it could preserve the remaining resilience of the brain. For families and clinicians, the study raises the possibility that treating atrial fibrillation effectively may have consequences extending beyond the heart.
The authors, led by Maria Eriksdotter and Nanbo Zhu at Karolinska Institutet, say the results support careful consideration of NOAC therapy when anticoagulation is clinically indicated for a person with atrial fibrillation and Alzheimer’s disease. They do not recommend using these medicines solely as an Alzheimer’s treatment, and the study cannot justify changing medication without medical supervision. Instead, the work suggests that the choice of anticoagulant may matter for more than stroke prevention and should be evaluated alongside bleeding risk, kidney health, frailty, other medications and a patient’s treatment goals. Randomized clinical trials will be needed to determine whether NOACs truly slow cognitive decline or whether the apparent advantage reflects differences between the patients who received them.
Subject of Research: People with atrial fibrillation and Alzheimer’s disease
Article Title: Oral anticoagulants, cognition, and clinical outcomes in atrial fibrillation and Alzheimer’s disease: a Swedish nationwide study
News Publication Date: 12 August 2026
Web References: https://academic.oup.com/eurheartj/article-lookup/doi/10.1093/eurheartj/ehag584
References: Zhu N, Xu H, Garcia-Ptacek S, Mitra S, Eriksdotter M. “Oral anticoagulants, cognition, and clinical outcomes in atrial fibrillation and Alzheimer’s disease: a Swedish nationwide study.” European Heart Journal. Online publication, 12 August 2026. DOI: 10.1093/eurheartj/ehag584
Keywords: Alzheimer’s disease, atrial fibrillation, NOACs, oral anticoagulants, warfarin, cognition, dementia, stroke prevention, cognitive decline, cardiovascular health, observational study, European Heart Journal
Tags: Atrial fibrillation-related stroke and cognitive impairmentBlood clot prevention and neurodegenerative diseaseBlood thinners and cognitive decline preventionCognitive performance in patients with atrial fibrillationComparison of warfarin and NOACs in cognitive healthImpact of anticoagulants on memory and reasoningLong-term effects of blood-thinning medicationsNon-vitamin K antagonist oral anticoagulants (NOACs) and Alzheimer’s diseaseRole of anticoagulants in reducing microinfarcts
